- Home
- PED vs BCAB Comparison
PED vs BCAB Comparison
Compare PED & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PED
- BCAB
- Stock Information
- Founded
- PED N/A
- BCAB 2007
- Country
- PED United States
- BCAB United States
- Employees
- PED N/A
- BCAB N/A
- Industry
- PED Oil & Gas Production
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- PED Energy
- BCAB Health Care
- Exchange
- PED Nasdaq
- BCAB Nasdaq
- Market Cap
- PED 48.8M
- BCAB 22.3M
- IPO Year
- PED N/A
- BCAB 2020
- Fundamental
- Price
- PED $0.65
- BCAB $0.39
- Analyst Decision
- PED Strong Buy
- BCAB Buy
- Analyst Count
- PED 2
- BCAB 2
- Target Price
- PED $1.63
- BCAB $1.00
- AVG Volume (30 Days)
- PED 575.7K
- BCAB 520.0K
- Earning Date
- PED 08-13-2025
- BCAB 08-07-2025
- Dividend Yield
- PED N/A
- BCAB N/A
- EPS Growth
- PED 2248.88
- BCAB N/A
- EPS
- PED 0.19
- BCAB N/A
- Revenue
- PED $40,173,000.00
- BCAB $11,000,000.00
- Revenue This Year
- PED N/A
- BCAB N/A
- Revenue Next Year
- PED $5.99
- BCAB N/A
- P/E Ratio
- PED $3.36
- BCAB N/A
- Revenue Growth
- PED 30.70
- BCAB N/A
- 52 Week Low
- PED $0.47
- BCAB $0.24
- 52 Week High
- PED $1.10
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- PED 47.22
- BCAB 45.46
- Support Level
- PED $0.64
- BCAB $0.36
- Resistance Level
- PED $0.81
- BCAB $0.40
- Average True Range (ATR)
- PED 0.05
- BCAB 0.04
- MACD
- PED -0.01
- BCAB -0.00
- Stochastic Oscillator
- PED 8.05
- BCAB 22.73
About PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.